Patents by Inventor Doris F. Cully

Doris F. Cully has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8163877
    Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Dermacentor variabilis ligand gated ion channel proteins. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding D. variabilis LGIC/GluCl channels, substantially purified forms of associated D. variabilis channel proteins and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Dermacentor variabilis LGIC/GluCl, which will be useful as insecticides and acaricides.
    Type: Grant
    Filed: January 8, 2010
    Date of Patent: April 24, 2012
    Assignee: Merial Limited
    Inventors: Doris F. Cully, Yingcong Zheng
  • Patent number: 7915010
    Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Rhipicephalus sanguineus glutamate gated chloride channels. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding R. sanguineus glutamate gated chloride channels, substantially purified forms of associated R. sanguineus glutamate gated chloride channels and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Rhipicephalus sanguineus glutamate gated chloride channels, which will be useful as insecticides.
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: March 29, 2011
    Assignee: Merial Limited
    Inventors: Jeffrey W. Warmke, Youfeng Yang, Doris F. Cully, Michel J. Hamelin
  • Publication number: 20100184064
    Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Dermacentor variabilis ligand gated ion channel proteins. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding D. variabilis LGIC/GluCl channels, substantially purified forms of associated D. variabilis channel proteins and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Dermacentor variabilis LGIC/GluCl, which will be useful as insecticides and acaricides.
    Type: Application
    Filed: January 8, 2010
    Publication date: July 22, 2010
    Inventors: Doris F. Cully, Yingcong Zheng
  • Patent number: 7674586
    Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Rhipicephalus sanguineus glutamate gated chloride channels. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding R. sanguineus glutamate gated chloride channels, substantially purified forms of associated R. sanguineus glutamate gated chloride channels and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Rhipicephalus sanguineus glutamate gated chloride channels, which will be useful as insecticides.
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: March 9, 2010
    Assignee: Merial Limited
    Inventors: Jeffrey W. Warmke, Youfeng Yang, Doris F. Cully, Michel J. Hamelin
  • Patent number: 7655440
    Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Dermacentor variabilis ligand gated ion channel proteins. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding D. variabilis LGIC/GluCl channels, substantially purified forms of associated D. variabilis channel proteins and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Dermacentor variabilis LGIC/GluCl, which will be useful as insecticides and acaracides.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: February 2, 2010
    Assignee: Merial Limited
    Inventors: Doris F. Cully, Yingcong Zheng
  • Patent number: 7645867
    Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Dermacentor variabilis ligand gated ion channel proteins. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding D. variabilis LGIC/GluCl channels, substantially purified forms of associated D. variabilis channel proteins and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Dermacentor variabilis LGIC/GluCl, which will be useful as insecticides and acaracides.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: January 12, 2010
    Assignee: Merial Limited
    Inventors: Doris F. Cully, Yingcong Zheng
  • Patent number: 7541432
    Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Rhipicephalus sanguineus glutamate gated chloride channels. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding R. sanguineus glutamate gated chloride channels, substantially purified forms of associated R. sanguineus glutamate gated chloride channels and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Rhipicephalus sanguineus glutamate gated chloride channels, which will be useful as insecticides.
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: June 2, 2009
    Assignee: Merial Limited
    Inventors: Jeffrey W. Warmke, Youfeng Yang, Doris F. Cully, Michel J. Hamelin
  • Publication number: 20080286770
    Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Rhipicephalus sanguineus glutamate gated chloride channels. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding R. sanguineus glutamate gated chloride channels, substantially purified forms of associated R. sanguineus glutamate gated chloride channels and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Rhipicephalus sanguineus glutamate gated chloride channels, which will be useful as insecticides.
    Type: Application
    Filed: January 5, 2007
    Publication date: November 20, 2008
    Inventors: Jeffrey W. Warmke, Youfeng Yang, Doris F. Cully, Michel J. Hamelin
  • Patent number: 7267964
    Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Dermacentor variabilis ligand gated ion channel proteins. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding D. variabilis LGIC/GluCl channels, substantially purified forms of associated D. variabilis channel proteins and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Dermacentor variabilis LGIC/GluCl, which will be useful as insecticides and acaracides.
    Type: Grant
    Filed: March 28, 2001
    Date of Patent: September 11, 2007
    Assignee: Merial Limited
    Inventors: Doris F. Cully, Yingcong Zheng
  • Patent number: 7244586
    Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Drosophila melanogaster ligand-gated ion channel proteins. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding Drosophila ligand-gated ion channel proteins, substantially purified forms of associated Drosophila ligand-gated ion channel proteins and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Drosophila melanogaster ligand-gated ion channel proteins, which will be useful as insecticides.
    Type: Grant
    Filed: February 26, 2001
    Date of Patent: July 17, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Doris F. Cully, Birgit Priest, Jeffrey Yuan, Yingcong Zheng
  • Patent number: 7220832
    Abstract: The present invention features Dermacentor variabilis GABA-gated chloride channel polypeptides and nucleic acids, and uses of such polypeptides and nucleic acids. D. variabilis is a widely distributed tick associated with different diseases. A preferred use of the present invention is to obtain compounds for preventing or treating a tick infestation.
    Type: Grant
    Filed: March 28, 2001
    Date of Patent: May 22, 2007
    Assignee: Merck & Co., Inc
    Inventors: Yingcong Zheng, Doris F. Cully, Steve W. Ludmerer
  • Patent number: 7202054
    Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Rhipicephalus sanguineus glutamate gated chloride channels. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding R. sanguineus glutamate gated chloride channels, substantially purified forms of associated R. sanguineus glutamate gated chloride channels and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Rhipicephalus sanguineus glutamate gated chloride channels, which will be useful as insecticides.
    Type: Grant
    Filed: March 28, 2001
    Date of Patent: April 10, 2007
    Assignee: Merial Limited
    Inventors: Jeffrey W. Warmke, Youfeng Yang, Doris F. Cully, Michel J. Hamelin
  • Publication number: 20030229215
    Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Rhipicephalus sanguineus glutamate gated chloride channels. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding R. sanguineus glutamate gated chloride channels, substantially purified forms of associated R. sanguineus glutamate gated chloride channels and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Rhipicephalus sanguineus glutamate gated chloride channels, which will be useful as insecticides.
    Type: Application
    Filed: September 23, 2002
    Publication date: December 11, 2003
    Inventors: Jeffrey W. Warmke, Youfeng Yang, Doris F. Cully, Michel J. Hamelin
  • Publication number: 20030208041
    Abstract: The present invention features Dermacentor variabilis GABA-gated chloride channel polypeptides and nucleic acids, and uses of such polypeptides and nucleic acids. D. variabilis is a widely distributed tick associated with different diseases. A preferred use of the present invention is to obtain compounds for preventing or treating a tick infestation.
    Type: Application
    Filed: September 25, 2002
    Publication date: November 6, 2003
    Inventors: Yingcong Zheng, Doris F. Cully, Steve W. Ludmerer
  • Publication number: 20030166144
    Abstract: Human, swine and rat growth hormone secretagogue receptors have been isolated, cloned and sequenced. Growth hormone secretagogue receptors are new members of the G-protein family of receptors. The growth hormone secretagogue receptors may be used to screen and identify compounds which bind to the growth hormone secretagogue receptor. Such compounds may be used in the treatment of conditions which occur when there is a shortage of growth hormone, such as observed in growth hormone deficient children, elderly patients with musculoskeletal impairment and recovering from hip fracture and osteoporosis.
    Type: Application
    Filed: November 25, 2002
    Publication date: September 4, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Joseph P. Arena, Doris F. Cully, Scott D. Feighner, Andrew D. Howard, Paul A. Liberator, James M. Schaeffer, Leonardus H. T. Van Der Ploeg
  • Publication number: 20030096984
    Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Dermacentor variabilis ligand gated ion channel proteins. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding D. variabilis LGIC/GluCl channels, substantially purified forms of associated D. variabilis channel proteins and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Dermacentor variabilis LGIC/GluCl, which will be useful as insecticides and acaracides.
    Type: Application
    Filed: September 23, 2002
    Publication date: May 22, 2003
    Inventors: Doris F. Cully, Yingcong Zheng
  • Patent number: 6531314
    Abstract: Human, swine and rat growth hormone secretagogue receptors have been isolated, cloned and sequenced. Growth hormone secretagogue receptors are new members of the G-protein family of receptors. The growth hormone secretagogue receptors may be used to screen and identify compounds which bind to the growth hormone secretagogue receptor. Such compounds may be used in the treatment of conditions which occur when there is a shortage of growth hormone, such as observed in growth hormone deficient children, elderly patients with musculoskeletal impairment and recovering from hip fracture and osteoporosis.
    Type: Grant
    Filed: June 3, 1998
    Date of Patent: March 11, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Joseph P. Arena, Doris F. Cully, Scott D. Feighner, Andrew D. Howard, Paul A. Liberator, James M. Schaeffer, Leonardus H. T. Van Der Ploeg
  • Patent number: 6358701
    Abstract: To date, L-glutamate-gated chloride (GluCl) channels have been observed only in invertebrate organisms. Modulators of this channel (either agonists or antagoinists) will interfere with neurotransmission. For example, agents such as avermectins activate the GluCl, causing paralysis due to blocking of neurotranmitter release, resulting in death of the organism. Because GluCl channels are invertebreate specific, they are excellent targets for the discovery of novel insecticides, anthelminths and parasiticides that will display a marked safety profile because of the lack of mechanism based toxicity in vertebrate organisms. The present specification discloses isolation of a cDNA clone from the cat flea Ctenocephalides felis (CfGluCl-1) that encodes a L-glutamate-gated chloride channel. Heterologous expression of CfGluCl-1 cRNA in Xenopus oocytes results in robust expression of a L-glutamate-gated chloride current and the channel is activated and potentiated by avermectins.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: March 19, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Jeffrey W. Warmke, Doris F. Cully, Adrian Etter, Philip S. Paress, Charles J. Cohen, Richard Brochu
  • Patent number: 6007998
    Abstract: A trans-activation assay for leptin is described. Leptin response elements are located proximal to a promoter, and the promoter region is operatively linked to a reporter gene. When leptin binds with the receptor, the reporter gene is transcribed.
    Type: Grant
    Filed: April 21, 1997
    Date of Patent: December 28, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Charles I. Rosenblum, Leonardus H. T. Van Der Ploeg, Sajjad A. Qureshi, Doris F. Cully, John W. Hess, Michael R. Tota, Fang Chen
  • Patent number: 5693492
    Abstract: DNA encoding glutamate and avermectin-sensitive chloride channels have been cloned and characterized. The protein is capable of forming channels selectively opened with either avermectin or glutamate. The cDNA has been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified. Receptor modulators active in the method disclosed herein are useful as ectoparasiticides, antiparasitic, anthelmenthic, acaracidal and insecticide agents.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: December 2, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Doris F. Cully, Joseph P. Arena, Philip S. Paress, Ken K. Liu